Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Q312: Biotech on a roll

Biotech continued to outperform the broader markets, with the BioCentury 100 Index up 7% and the NASDAQ Biotechnology Index up 10% in 3Q12 versus a 6% rise in the S&P 500. Excluding partnership monies, the industry raised (mostly from debt and follow-on offerings) $13 billion last quarter—the fourth highest of any quarter since 2000. Only four companies completed initial public offerings (IPOs). About $1.8 billion was raised by private biotechs, up from $1.4 billion in 2Q12 and $1.4 billion a year ago.

Stock market performance

Notable 3Q12 deals

Global biotech industry financing

Global biotech initial public offerings

Global biotech venture capital investment

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yang, W. Q312: Biotech on a roll. Nat Biotechnol 30, 1165 (2012). https://doi.org/10.1038/nbt.2457

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing